Several other analysts have also recently weighed in on RTRX. BidaskClub cut Retrophin from a hold rating to a sell rating in a report on Thursday, April 4th. Zacks Investment Research raised Retrophin from a strong sell rating to a hold rating in a report on Wednesday, February 27th. Svb Leerink reaffirmed an outperform rating on shares of Retrophin in a report on Tuesday, February 26th. Finally, TheStreet cut Retrophin from a c- rating to a d+ rating in a report on Friday, February 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $50.50.
NASDAQ:RTRX opened at $20.05 on Thursday. Retrophin has a twelve month low of $19.57 and a twelve month high of $33.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 4.68 and a current ratio of 4.74.
Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.42. Retrophin had a negative return on equity of 33.53% and a negative net margin of 62.51%. The firm had revenue of $43.77 million for the quarter, compared to analysts’ expectations of $43.54 million. During the same quarter last year, the firm posted $0.07 EPS. The company’s revenue was up 3.8% compared to the same quarter last year. Sell-side analysts predict that Retrophin will post -2.47 earnings per share for the current fiscal year.
In related news, CEO Steve Aselage sold 2,130 shares of the firm’s stock in a transaction dated Tuesday, February 12th. The stock was sold at an average price of $21.44, for a total transaction of $45,667.20. Following the transaction, the chief executive officer now directly owns 258,707 shares of the company’s stock, valued at approximately $5,546,678.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider William E. Rote sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $21.48, for a total value of $53,700.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,917 shares of company stock worth $277,140. 3.67% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. MetLife Investment Advisors LLC raised its holdings in shares of Retrophin by 55.7% during the 3rd quarter. MetLife Investment Advisors LLC now owns 29,333 shares of the biopharmaceutical company’s stock valued at $843,000 after buying an additional 10,491 shares in the last quarter. Handelsinvest Investeringsforvaltning raised its holdings in shares of Retrophin by 33.8% during the 4th quarter. Handelsinvest Investeringsforvaltning now owns 66,916 shares of the biopharmaceutical company’s stock valued at $1,514,000 after buying an additional 16,916 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Retrophin during the 3rd quarter valued at about $2,296,000. Macquarie Group Ltd. raised its holdings in shares of Retrophin by 17.6% during the 4th quarter. Macquarie Group Ltd. now owns 2,265,924 shares of the biopharmaceutical company’s stock valued at $51,278,000 after buying an additional 339,588 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of Retrophin by 16.1% during the 3rd quarter. Wells Fargo & Company MN now owns 110,585 shares of the biopharmaceutical company’s stock valued at $3,177,000 after buying an additional 15,335 shares in the last quarter.
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Story: How to track put option volume
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.